| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119, 2020 | 592 | 2020 |
| CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 351 | 2021 |
| Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience LJ Nastoupil, MD Jain, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 133 | 2018 |
| Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma JH Baird, DJ Epstein, JS Tamaresis, Z Ehlinger, JY Spiegel, J Craig, ... Blood advances 5 (1), 143-155, 2021 | 112 | 2021 |
| Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy Z Good, JY Spiegel, B Sahaf, MB Malipatlolla, ZJ Ehlinger, S Kurra, ... Nature Medicine 28 (9), 1860-1871, 2022 | 99 | 2022 |
| Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy JY Spiegel, S Dahiya, MD Jain, J Tamaresis, LJ Nastoupil, MT Jacobs, ... Blood, The Journal of the American Society of Hematology 137 (13), 1832-1835, 2021 | 97 | 2021 |
| Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi … MJ Frank, NM Hossain, A Bukhari, E Dean, JY Spiegel, GK Claire, I Kirsch, ... Journal of Clinical Oncology 39 (27), 3034, 2021 | 96 | 2021 |
| A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies JF Deeken, H Wang, M Hartley, AK Cheema, B Smaglo, JJ Hwang, AR He, ... Cancer chemotherapy and pharmacology 81, 587-596, 2018 | 80 | 2018 |
| Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies N Hossain, B Sahaf, M Abramian, JY Spiegel, K Kong, S Kim, ... Blood 132, 490, 2018 | 68 | 2018 |
| CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma JH Baird, MJ Frank, J Craig, S Patel, JY Spiegel, B Sahaf, JS Oak, ... Blood, The Journal of the American Society of Hematology 137 (17), 2321-2325, 2021 | 64 | 2021 |
| Molecular imaging of chimeric antigen receptor T cells by ICOS-ImmunoPET F Simonetta, IS Alam, JK Lohmeyer, B Sahaf, Z Good, W Chen, Z Xiao, ... Clinical Cancer Research 27 (4), 1058-1068, 2021 | 63 | 2021 |
| Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy JY Spiegel, C McNamara, JA Kennedy, T Panzarella, A Arruda, T Stockley, ... Blood advances 1 (20), 1729-1738, 2017 | 61 | 2017 |
| Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR … MD Jain, MT Jacobs, LJ Nastoupil, JY Spiegel, G Feng, Y Lin, ... Blood 134, 245, 2019 | 57 | 2019 |
| Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas BJ Sworder, DM Kurtz, SK Alig, MJ Frank, N Shukla, A Garofalo, ... Cancer Cell 41 (1), 210-225. e5, 2023 | 51 | 2023 |
| Phase I trial using CD19/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL) LM Schultz, LS Muffly, JY Spiegel, S Ramakrishna, N Hossain, C Baggott, ... Blood 134, 744, 2019 | 51 | 2019 |
| CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering RG Majzner, MJ Frank, C Mount, A Tousley, DM Kurtz, B Sworder, ... Blood 136, 53-54, 2020 | 43 | 2020 |
| Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy A Johnsrud, J Craig, J Baird, J Spiegel, L Muffly, J Zehnder, J Tamaresis, ... Blood advances 5 (21), 4465-4475, 2021 | 38 | 2021 |
| Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia L Muffly, V Sundaram, C Chen, I Yurkiewicz, E Kuo, S Burnash, ... Blood advances 5 (16), 3147-3151, 2021 | 27 | 2021 |
| Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience W Alduaij, CJ McNamara, A Schuh, A Arruda, M Sukhai, N Kanwar, ... HemaSphere 2 (3), e44, 2018 | 24 | 2018 |
| Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US Lymphoma CAR-T Consortium. JY Spiegel, S Dahiya, MD Jain, LJ Nastoupil, A Ghobadi, Y Lin, ... Journal of Clinical Oncology 37 (15_suppl), 7517-7517, 2019 | 21 | 2019 |
